Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Central Tolerance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    133 result(s) found for: Central Tolerance. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2007-004250-81 Sponsor Protocol Number: AKREMITOLFMRI1 Start Date*: 2007-09-11
    Sponsor Name:Helsinki University Central Hospital, Pain Clinic
    Full Title: Acute opioid tolerance as revealed by functional magnetic resonance imaging.
    Medical condition: akuutti opioiditoleranssi
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052804 Drug tolerance LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2013-004065-13 Sponsor Protocol Number: Metform02 Start Date*: 2013-11-27
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: Metformin treatment vs a diabetes model of antenatal care in women with mild fasting hyperglycaemia diagnosed in pregnancy: a pilot study
    Medical condition: Gestational diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10000138 Abnormal glucose tolerance in pregnancy LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011403-23 Sponsor Protocol Number: CHIC2009-01 Start Date*: 2009-08-10
    Sponsor Name:Centre Hospitalier Intercommunal de Créteil
    Full Title: ETUDE PILOTE SUR L’EFFICACITE ET LA TOLERANCE DES INJECTIONS INTRA-VITREENNES DE LUCENTIS (RANIBIZUMABÒ) A LA PHASE INITIALE DES OCCLUSIONS DE LA VEINE CENTRALE DE LA RETINE
    Medical condition: Central retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007972 Central retinal vein occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011003-23 Sponsor Protocol Number: GFT505-209-4 Start Date*: 2009-05-28
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double ...
    Medical condition: patients presenting with impaired glucose tolerance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036481 Pre-diabetes LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003031-35 Sponsor Protocol Number: R04049 Start Date*: 2015-11-20
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: A Single Centre Study Investigating the Safety and Efficacy of an Immune Modulation Regimen in Mitigating the Alloimmune Response to Intravenous Laronidase in Infants With Severe Mucopolysaccharido...
    Medical condition: Severe Mucopolysaccharidosis Type I (Hurler syndrome, MPS IH)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10028094 Mucopolysaccharidosis IH LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000080-85 Sponsor Protocol Number: 17-245 Start Date*: 2018-11-29
    Sponsor Name:CHU CAEN
    Full Title: Pilot study of the pharmacokinetic profile of paracetamol subcutaneously versus intravenously in patients receiving palliative care
    Medical condition: Major patients in palliative care
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10059513 Palliative care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002517-18 Sponsor Protocol Number: PROICM2020-04GAB Start Date*: 2020-10-19
    Sponsor Name:Institut régional du cancer de Montpellier (ICM)
    Full Title: Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with ...
    Medical condition: Locally advanced adenocarcinoma of pancreas
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005131-15 Sponsor Protocol Number: 2008/0828 Start Date*: 2008-12-19
    Sponsor Name:CHRU de Lille
    Full Title: ETUDE DE LA PHARMACOCINETIQUE DE L’ASSOCIATION PIPERACILLINE – TAZOBACTAM EN UTILISATION INTRA-VEINEUSE CONTINUE CHEZ L’ENFANT NEUTROPENIQUE FEBRILE .
    Medical condition: febrile episodes in neutropenic patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10053223 Febrile aplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001614-94 Sponsor Protocol Number: 15-PP-03 Start Date*: 2015-07-03
    Sponsor Name:Centre Hospitalier Universitaire de Nice
    Full Title: Hepatoprotective role of SMOFlipid® used in short-term parenteral nutrition in an Onco-Hematology Pediatric Population, pilot study
    Medical condition: parenteral nutrition in an Onco-Hematology Pediatric Population
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004865 10065877 Dietary and nutritional therapies HLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000177-23 Sponsor Protocol Number: P170930J Start Date*: 2021-04-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: IMMUNOTHERAPY WITH INTRAVENOUS IMMUNOGLOBULINS, CYCLOPHOSPHAMIDE AND METHYLPREDNISOLONE IN PATIENTS WITH PARANOPLASTIC SENSITIVE NEURONOPATHIES WITH ANTI-HU ANTIBODIES
    Medical condition: Paraneoplastic Neurological Syndromes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004337-41 Sponsor Protocol Number: GFT505-207-2 Start Date*: 2008-01-11
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059179 Abdominal obesity LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017193-20 Sponsor Protocol Number: S51994 Start Date*: 2010-01-28
    Sponsor Name:UZLeuven
    Full Title: Effect of naloxone and methylnaltrexone on satiety, gastric sensitivity, and accommodation to food in healthy volunteers.
    Medical condition: healthy volunteers none; this is a physiological study to investigate the influence of opioid antagonism on gastric sensorimotor function
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000929-42 Sponsor Protocol Number: TCH-306 Start Date*: 2021-06-09
    Sponsor Name:Ascendis Pharma Endocrinology Division A/S
    Full Title: foresiGHt: A multicenter, randomized, parallel-arm, placebo- controlled (double- blind) and active-controlled (open-label) trial to compare the efficacy and safety of once-weekly lonapegsomatropin ...
    Medical condition: Adult Growth Hormone Deficiency (AGHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed) ES (Ongoing) NL (Completed) GR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016604-23 Sponsor Protocol Number: CACZ885I2207 Start Date*: 2010-05-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, placebo-controlled, randomized study to compare the effect of a subcutaneous canakinumab administration to placebo in patients with Impaired Glucose Tolerance or patie...
    Medical condition: Impaired Glucose Tolerance and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020113-85 Sponsor Protocol Number: CSLCT-BIO-l0-67 Start Date*: 2011-09-20
    Sponsor Name:CSL Behring GmbH
    Full Title: A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to evaluate Plasma-Derived Antihaemophilic Factor/von Willebrand Factor Concentrate (Biostate®) for Immune To...
    Medical condition: Male paediatric subjects with Haemophilia A who develped high titre antibodies to human coagulation Factor VIII
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10018941 Haemophilia NOS LLT
    Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) FR (Completed) AT (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005054-23 Sponsor Protocol Number: V00251 IV 201 Start Date*: 2007-12-07
    Sponsor Name:PIERRE FABRE MEDICAMENT - IRPF
    Full Title: A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis.
    Medical condition: V0251 is a new investigational antivertiginous agent which is being developed for the treatment of symptomatic vertiginous crisis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047340 Vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) DE (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-002666-47 Sponsor Protocol Number: SOAP1 Start Date*: 2017-11-02
    Sponsor Name:Dpt. of Ophthalmology, Rigshospitalet-Glostrup
    Full Title: Effect of drop-less surgery compared to topical NSAID alone and combination of steroid and NSAID on central macular thickness after cataract surgery, a randomized controlled trial
    Medical condition: Postoperative cystoid macular edema following cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10070634 Irvine-Gass syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-006237-42 Sponsor Protocol Number: 39085 Start Date*: 2012-12-12
    Sponsor Name:Erasmus University Rotterdam
    Full Title: Optimization of exercise therapy in type 2 diabetes mellitus
    Medical condition: Insulin resistance, endothelial dysfunction, cardiovascular fitness, cardio-respiratory responses, glycemic control in deconditioned non-insulin dependent type 2 diabetes patients
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004045-16 Sponsor Protocol Number: ET18-272 Start Date*: 2019-03-14
    Sponsor Name:Centre Léon Bérard
    Full Title: REGOSTA – A randomized, placebo-controlled, double-blinded, multicentre study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bo...
    Medical condition: Patients with bone sarcomas other than Ewing sarcoma or chondrosarcoma or chordoma, who have no residual disease after neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002629-31 Sponsor Protocol Number: ET19-144 Start Date*: Information not available in EudraCT
    Sponsor Name:Centre Léon Bérard
    Full Title: REGOMAIN – A randomized, placebo-controlled, double-blinded, multicentre, comparative phase II study of the efficacy of regorafenib as maintenance treatment in patients with high grade bone sarcoma...
    Medical condition: Patients with high grade bone sarcomas (HGBS) at diagnosis or first relapse and without complete remission after standard treatment
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA